Skip to main content
XBIO
NASDAQ Life Sciences

Xenetic Q3 Loss Widens to $1.7M as Santersus Deal Costs Hit G&A; Cash Falls to $5.8M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.66
Mkt Cap
$3.89M
52W Low
$1.58
52W High
$4.939
52W Position info
5.1% above low
Off High info
66% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

XBIO is trading near its 52-week low of $1.58 (5.1% above the low) on light trading volume (0.3× avg).

Summary

Xenetic's Q3 net loss widened to $1.70M from $0.51M as Santersus deal costs drove G&A up 138%, while royalty revenue fell 29.4% and cash dropped to $5.81M. The all-stock Santersus merger still awaits a stockholder vote.


Key Events · Earnings and Guidance · XBIO

  • Q3 Net Loss Widens Sharply

    Net loss was $1.70M for the three months ended September 30, 2026, versus $0.51M a year earlier; nine-month net loss reached $3.08M versus $2.10M.

  • Deal Costs Drive G&A Up 138%

    General and administrative expense rose to $1.94M in Q3 from $0.82M, attributed to legal and financial advisory services related to the Santersus Acquisition.

  • Royalty Revenue Falls 29.4%

    Q3 revenue dropped to $0.73M from $1.03M on lower Takeda royalty revenue; nine-month revenue was roughly flat at $2.19M versus $2.21M.

  • Cash Falls to $5.8M

    Cash was $5.81M at September 30, 2026, down from $7.88M at December 31, 2025; working capital fell to $4.1M from $7.1M. Management says resources fund operations for at least twelve months.


Analysis · XBIO · Life Sciences

Cost, not operations, is the quarter's headline: general and administrative expense more than doubled to $1.94M on legal and financial advisory work for the pending all-stock Santersus acquisition, pushing the net loss to $1.70M from $0.51M a year ago. Royalty revenue from the Takeda sublicense slipped 29.4% to $0.73M, so the company is burning cash while it waits on the deal. Cash fell to $5.81M from $7.88M at year-end, and management says existing resources cover at least twelve months — but the combined company will need substantial new capital, and the filing flags a possible reverse split to hold Nasdaq listing. The merger still needs a Xenetic stockholder vote, and Santersus holders are set to own roughly 85% of the combined company.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XBIO was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.58 to $4.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XBIO - Latest Insights

XBIO
Sep 23, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.47
Real-time Price: $1.66 info
Change: -$0.810 (-33%) info
Market Cap: $3.89M info
XBIO
Sep 16, 2026, 10:28 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.66 info
Change: -$0.5578 (-25%) info
Market Cap: $3.89M info
XBIO
Sep 16, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $1.66 info
Change: -$2.61 (-61%) info
Market Cap: $3.89M info
XBIO
Sep 16, 2026, 7:00 AM EDT
Source: ACCESS Newswire
Importance Score:
9
Price at Filing: $4.27
Real-time Price: $1.66 info
Change: -$2.61 (-61%) info
Market Cap: $3.89M info
XBIO
Aug 07, 2026, 8:44 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.04
Real-time Price: $1.66 info
Change: -$1.38 (-45%) info
Market Cap: $3.89M info